Abstract Tumor necrosis factor-a (TNFa) and thrombospondin-1 (TSP-1) are well-known mediators of inflammation. However, a causal relationship between TNFa stimuli and TSP-1 expression in endothelial cell stress, and the underlying mechanisms has not yet been investigated. In our study, human microvascular endothelial cells (hMEC) were treated with TNFa and analyzed for endothelial dysfunction, TSP-1 expression, and associated mechanisms. TNFa treatment induced a dose-dependent increase in TSP-1 expression in hMEC associated with increased endothelial permeability, apoptosis, and reduced proliferation. Whereas TNFa activated Akt, ERK, and P38 mitogen-activated protein kinase (P38 MAPK) simultaneously in hMEC, inhibitors of Akt and P38 MAPK, but not ERK blunted TNFa-induced TSP-1 expression. Silencing of NFjB gene had no significant effect on TNFa-induced TSP-1 expression. Our study demonstrates the novel role of TNFa in inducing inflammatory stress response in hMEC through Akt-and P38 MAPK-mediated expression of TSP-1, independent of NFjB signaling.
Introduction
Tumor necrosis factor alpha (TNFa), a mediator of inflammation, acts on the endothelium, the first line of action during inflammatory stimuli [1] . Activated macrophages, the major source of TNFa, have the ability to lyse many cell types including tumor cells [2] . As a result of the cellular stress inflicted by TNFa, endothelial cells undergo apoptosis [3] leading to barrier breakdown and increased vascular permeability aiding migration of inflammatory cells into the tissue environment [2, 4] . TNFa deregulation has been reported in many human diseases such as Alzheimer's disease [5] , cancer [6] , depression [7] , and inflammatory bowel disease [8] . Although TNFa signaling pathway is considered as a new therapeutic strategy for inflammatory diseases [9] , lack of knowledge on the precise molecular and cellular events in TNFa-induced stress response limits its application in anti-inflammation therapy.
Thrombospondin-1 (TSP-1) is a multifunctional 450 kDa glycoprotein, which is secreted by many cell types including endothelial cells, and are also stored in the platelet a-granules [10] . Whereas macrophages, fibroblasts, and endothelial cells are known to lodge cell surface TSP-1 during tissue injury or inflammation [11] [12] [13] [14] [15] , TSP-1 is also essential for the extracellular matrix remodeling in skin and other tissues [16] , thus suggesting a key role for TSP-1 in the inflammatory response and post-inflammatory tissue remodeling. TSP-1 acts as a chemo-attractant and increases the adherence of monocyte and neutrophils to the endothelium [17] [18] [19] [20] . Due to its affinity towards multiple cell surface receptors, TSP-1 elicits pleiotropic effects in many cell types. Whether or not TSP-1 is required for TNFainduced inflammation is not clear.
In the current study, we report that treatment with TNFa results in cellular stress in human microvascular endothelial cells (hMEC) via activation of P38 MAPK in a dosedependent manner, without compromising the Akt and ERK survival pathways. Interestingly, activation of P38 MAPK by TNFa leads to hMEC apoptosis despite co-activation of Akt and ERK. Increased hMEC stress by TNFa was associated with increased synthesis and secretion of TSP-1 by the hMEC, which is blunted by pharmacological inhibition of Akt or P38 MAPK, but not ERK. However, gene silencing of NFjB, a transcription factor regulated by Akt and P38 MAPK, did not show any effect of TSP-1 expression. Our study provides novel insight into the role of TNFa/TSP-1 axis in hMEC inflammatory stress response via Akt and P38 MAPK activation independent of NFjB, and renders reasonable optimism for utilizing this pathway for the treatment of inflammatory diseases.
Materials and Methods

Reagents, cell lines, and antibodies
Telomerase-immortalized hMEC were purchased from ATCC (Manassas, VA). The primary antibodies for TSP-1, phospho-Akt S473 , panAkt, phospho-Erk1/2, phospho-P38 MAPK, NFjB p65, cleaved caspase 3, cleaved caspase 9, and GADPH were from Cell Signaling Technology (Danvers, MA). NFjB p65 SiRNA was purchased from SA Biosciences (Frederick, MD). Piceatannol and TSP-1 ELISA kit was purchased from R&D systems (Minneapolis, MN). TNFa was obtained from Fisher Scientific (Pittsburgh, PA). Thiazolyl blue tetrazolium bromide (MTT) was purchased from Amresco (Solon, OH).
Electric cell-substrate impedance sensing (ECIS) method
ECIS assay was performed as previously described [21, 22] . Briefly, 8-well chamber arrays covered which goldplated electrodes were filled with 400 ll of electrode-stabilizing solution and incubated for 30 min. Next, arrays were washed with 400 ll complete media and 5 9 10 5 hMEC in total 400 ll of media was added directly into the each array well. Then, cells were cultured until a monolayer is formed (*48 h), followed by treatment with 0, 1, 5, 10, 25, and 50 ng/ml TNFa and real-time analysis using ECIS instrument up to 12 h. ECIS equipment and arrays were purchased from Applied Biophysics (Troy, NY).
Immunocytochemistry and fluorescent imaging
Immunofluorescence staining was performed as described previously [23] . Briefly, hMEC monolayer plated on 8-well chamber slides was treated with various doses of TNFa for 12 h. Next, cells were fixed with 2 % paraformaldehyde in 1 9 PBS followed by permeabilization with 0.1 % Triton X-100 in 19 PBS. Nonspecific staining was blocked with 2 % BSA for 1 h at room temperature. Monolayers were then incubated with Alexa Fluor 488-labeled phalloidin (dilution 1:1000) (Life technologies, Carlsbad, CA) at room temperature for 1 h. The slides were mounted with Vectashield (Vector Laboratories, PA), and imaged by a Zeiss fluorescent microscope.
Western blot analysis
Western blot analysis was performed as described previously [21, 22] . In the first set of experiments, Western blot analysis was carried out to measure the phosphorylation and/or expression level of TSP-1, pAkt, pERK, pP38 MAPK, cleaved caspase 3 and 8, and NFjB p65 in the conditioned media and/or cell lysates after dose-dependent treatment with TNFa. In order to do that, hMEC were plated in 6-well plates using EMB complete media (2 ml/ well) and allowed to attach for 48 h prior to treatment. Next, cells were washed with PBS and incubated in serumfree media supplemented with different concentrations of TNFa (0, 1,5, 10, 25, and 50 ng/ml) for 12 h. Next, conditioned media were collected and cell lysates were prepared. Protein estimation was performed using D c protein assay (Bio-Rad, Hercules, CA). Samples (30 lg of protein/ well) were separated on 8 % SDS-PAGE gel and then transferred to PVDF membranes. Membranes were blocked with 5 % milk blocking buffer for 1 h, and incubated with primary antibodies against TSP-1 (1:1000 dilution), GADPH (1:5000 dilution), pAkt (1:1000 dilution), panAkt (1:1000 dilution), pErk (1:1000 dilution), cleaved caspase 3 (1:1000 dilution), cleaved caspase 8 (1:1000 dilution), NFjB p65 (1:1000 dilution), and pP38 MAPK (1:500 dilution) overnight at 4°C. Membranes were washed with 19 TBST and incubated with secondary antibodies at room temperature for 1 h. Membranes were then washed again with 19 TBST and enhanced chemiluminescence was used to detect the signal. The data are presented as mean ± SD (n = 3). In the second set of experiments, Western blot analysis was performed to measure the phosphorylation and/or expression level of TSP-1 in cell lysates and the conditioned media after treatment with 10 lM SH-5 (Akt inhibitor), 10 lM U0126 (Mek1/2 inhibitor), and 5 lM SB239063 (P38 MAPK inhibitor). To do this, hMEC cells were plated in 6-well plates using EMB complete media (2 ml/well) and allowed to attach for 48 h prior to treatment, and the samples were processed as above.
ELISA assay for TSP-1
For ELISA assay, hMEC control SiRNA and NFjBSi RNA (2 pM or 5 ll of each SiRNA was transfected using lipofectamine and allowed to express for 72 h) were plated in 6-well plates using EMB complete media (2 ml/well) and allowed to attach for 48 h prior to treatment (a total time of 72 h after SiRNA transfection). Next, cells were washed with PBS and incubated in serum-free media supplemented with 10 ng/ml of TNFa for 12 h. Next, conditioned media were collected and subjected for ELISA assay for the secreted TSP-1. ELISA analysis was performed using the Quantikine Human TSP-1 solid-phase Immunoassay kit (R&D systems, Minneapolis, MN) according to the manufacturer's protocol.
3-(4,3-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay
MTT assay was performed as previously described [21] . Briefly, hMEC cells were plated in 96-well plates using EMB complete media (100 ll/well). After the formation of monolayer (*48 h), cells were treated with various doses of TNFa for 12 h in serum-free media. Media were removed and cells were treated with 150 ll (0.5 mg/ml) of MTT/well for 3 h. Absorbance was measured at a wavelength of 570 nm.
Trypan blue assay
Trypan blue assay was performed as previously described [24] . Briefly, hMEC were plated in 96-well plates using EMB complete media (100 ll/well). After the formation of monolayer (48 h), cells were treated with various doses of TNFa for 12 h in serum-free media. Then, serum-free media were removed and cells were detached by 25 ll/well of trypsin followed by adding 25 ll of Trypan blue solution. Total and dead cells were counted using hemocytometer under light microscope.
Apoptosis assay
Apoptosis assay was performed as previously described [21, 22] and determined based on cytoplasmic histoneassociated DNA fragments detection, quantified by the cell death detection ELISA PLUS kit (Roche Applied Science, Indianapolis, IN) according to the manufacturer's protocol. Briefly, hMEC were plated in 96-well plates at a density of 10 4 cells/well. After 48 h, cells were treated with treatment with various doses of TNFa for 12 h. Next, cells were lysed and centrifuged at 2009g for 10 min, and the collected supernatant was subjected to ELISA apoptosis detection plate. The absorbance was measured at 405 nm (reference wavelength, 492 nm).
Statistical analysis
Results were expressed as mean ± SD for either n = 3 experiments (Western blots and ECIS) or n = 6 (MTT, viability, and apoptosis assays). Paired two-tailed student t test was used to determine the level of significance. Twoway ANOVA was used to determine the statistical analysis of data with 3 or more groups. A 'p value' less than 0.05 were considered statistically significant.
Results
TNFa induces endothelial-barrier permeability
Since endothelial cells are the first to respond to any inflammatory stimuli, we determined whether TNFa can directly modulate the endothelial-barrier. Our results indicated that TNFa induces endothelial-barrier permeability in a dose-dependent manner in a highly sensitive ECIS method that measures endothelial-monolayer resistance (Fig. 1a, b) . Whereas as little as 1 ng/ml TNFa was able to significantly induce breakdown of the hMEC-barrier, maximum effect was seen at 25 ng/ml concentrations (Fig. 1b) . Interestingly, at 50 ng/ml dose of TNFa, a minimum level of recovery in endothelial-barrier resistance was noticed as compared to 25 ng/ml dose. Our immunocytochemistry analysis with phalloidin revealed that TNFa induces cytoskeletal changes leading endothelial-barrier junction gap formation and vascular permeability (Fig. 1c) .
TNFa induces synthesis and secretion of TSP-1 by hMEC and increases activating phosphorylation of Akt, P38 MAPK, and ERK Many clinical studies have suggested a correlation between activation of TNFa pathway and increased expression of TSP-1, another pro-inflammatory protein. Hence, we determined whether TNFa is able to directly regulate the expression of TSP-1 in hMEC. Our data indicated that treatment with TNFa results in a dose-dependent increase in the total expression of TSP-1 both in the cell lysates and
the conditioned media (Fig. 2a, b) . Interestingly, as observed in the endothelial-monolayer permeability study, although treatment with 50 ng/ml TNFa resulted in increased expression of TSP-1 in cell lysates as compared to 25 ng/ml dose, levels of secreted TSP-1 in the conditioned media was lesser in 50 ng/ml dose as compared to 25 ng/ml treated hMEC monolayers (Fig. 2a, b) . Surprisingly, both the survival pathways, Akt and ERK signaling as well as stress-activated P38 MAPK pathway, were observed to be significantly activated together by TNFa in hMEC in a dose-dependent manner (Fig. 2c, d ).
TNFa-mediated cell stress induces apoptosis and inhibits survival and proliferation of hMEC in vitro
Whereas both Akt and ERK pathways activate cell survival and proliferation in mammalian cells, respectively, P38 MAPK is involved in the regulation of cell stress and apoptosis. Since TNFa was able to activate Akt, ERK, and P38 MAPK simultaneously, we determined what the net effect of these signaling pathways will be on hMEC survival, apoptosis, and proliferation. Our results indicated that TNFa treatment results in a significant inhibition of proliferation (Fig. 3a) , cell survival (Fig. 3b) , and induces apoptosis (Fig. 3c ) in hMEC in a dose-dependent manner. Interestingly, even though significant reduction in cleaved caspase 3 expression in hMEC was noticed upon treatment with P38 MAPK inhibitor SB239063, neither P38 MAPK inhibition nor Akt inhibition using SH-5 exhibited any effect on TNFa-induced expression of cleaved caspase 3 (Fig. 4a, b ) and cleaved caspase 8 (Fig. 4a, c ) in hMEC. These results indicated that although Akt, P38 MAPK, and ERK pathways were activated in hMEC in response to TNFa treatment, TNFa was able to overcome the cell survival and proliferation effects of these kinases in hMEC in induction of apoptosis.
Pharmacological inhibition of Akt and P38 MAPK, but not ERK blunted TNFa-induced TSP-1 synthesis by hMEC
Since TNFa was able to activate Akt, ERK, and P38 MAPK simultaneously, we next sought to determine which of these pathways are responsible for the regulation of synthesis and secretion of TSP-1 by the hMEC. To do this, we treated hMEC monolayers with 5 ng/ml TNFa in the absence and presence of pharmacological inhibitors Akt (10 lM SH-5), Mek1/2 (10 lM U0126), or P38 MAPK (5 lM SB239063) for 12 h in serum-free media. Our results indicated that while low dose of TNFa (5 ng/ml) was able to significantly increase TSP-1 expression both in hMEC lysates and the conditioned media, inhibition of either P38 MAPK or Akt blunted the TNFa-induced synthesis and secretion of TSP-1 by hMEC (Fig. 5a-c) . Treatment with either Akt or P38 MAPK inhibitors reduced TSP-1 expression in the cell lysates and the conditioned media to below the basal level of expression by the control, vehicle-treated hMEC monolayers (Fig. 5a-c) . Our data thus indicated that both Akt and P38 MAPK activities are necessary for the expression of TSP-1 by hMEC in response to TNFa.
Pharmacological inhibition or gene silencing of NFjB had no significant effect on TNFa-induced TSP-1 synthesis by hMEC
We next determined if TNFa-induced TSP-1 expression involved activation of pro-inflammatory transcription factor NFjB. In our results, piceatannol an NFjB inhibitor although did not exhibit any effect on TSP-1 expression in hMEC lysates, a high dose of 100 lM induced TSP-1 expression (Fig. 6a) . In contrast, although lower doses on piceatannol had no effect on TNFa-induced TSP-1 synthesis in hMEC, 100 lM piceatannol demonstrated a significant inhibitory effect (Fig. 6a) . However, SiRNAmediated knockdown of NFjB p65 did not show any effect on the TNFa-induced TSP-1 expression (Fig. 6b) . Our analysis of the hMEC-conditioned medium for TSP-1 through an ELISA assay further confirmed that silencing of NFjB in hMEC had no significant effect on TNFa-induced TSP-1 secretion (Fig. 6c, d) . Interestingly, we observed changes in TSP-1 expression at higher doses of piceatannol, which was once again opposite in control versus Fig. 6 TNFa-induced TSP-1 expression in hMEC was reversed upon pharmacological or genetic inhibition of NFjB. a Representative Western blot images of hMEC lysates treated with 0, 25, 50, and 100 lM doses of NFjB inhibitor Piceatannol in the presence and absence of 10 ng/ml TNFa incubated for 12 h in serum-free media, probed with antibodies against TSP-1. Bar graph showing densitometry analysis of amount of TSP-1 in cell lysates in response to 0, 25, 50, and 100 lM doses of NFjB inhibitor Piceatannol in the presence and absence of 10 ng/ml TNFa incubated for 12 h in serumfree media. b Representative Western blot images of control and SiNFjB expressing hMEC lysates treated with 10 ng/ml TNFa, incubated for 12 h in serum-free media, probed with antibodies against TSP-1. Bar graph showing densitometry analysis of amount of TSP-1 in control and SiNFjB expressing hMEC lysates in response to 10 ng/ml TNFa, incubated for 12 h in serum-free media. c Bar graph showing the amount of TSP-1 in control and SiNFjB expressing hMEC-conditioned media in response to 10 ng/ml TNFa, incubated for 12 h in serum-free media measured using ELISA. d Bar graph showing relative fold changes in TSP-1 levels in control and SiNFjB expressing hMEC-conditioned media in response to 10 ng/ml TNFa, incubated for 12 h in serum-free media measured using ELISA. Data presented as mean ± SD (n = 3), *p \ 0.05, TNFa-treated hMECs (Fig. 6a) . This, we think is due to the toxicity and/or off-target effects of supra-optimal doses of piceatannol. Our data thus indicated that Akt-and P38 MAPK-mediated expression of TSP-1 by hMEC in response to TNFa was independent of NFjB activity.
Discussion
Integral role of TNFa in mediating inflammation has been indisputably demonstrated [25] . However, the mechanism regulating TNFa-mediated inflammatory response is only partly characterized. Among the various steps involved in an inflammatory response to stimuli, first and the foremost is activation of endothelium to express recognition receptors for inflammatory cells, barrier breakdown, and sustenance of vascular leakage for a longer period of time so as to assist in the exudation of plasma components and infiltration of inflammatory cells across endothelial-barrier [26] . In the current study, we investigated the specific effects of TNFa on hMEC-barrier and the mechanisms how TNFa mediate endothelial-stress response that prepares the endothelium for plasma exudation and infiltration of inflammatory cells. Our study revealed several novel details on the mechanisms regulating TNFa-induced endothelial stress and how TNFa sustains and/or amplifies its effects. First, our study showed that treatment with TNFa results in a dose-and time-dependent breakdown of endothelial-barrier as evidenced by the real-time changes in endothelial-barrier resistance measured by a highly sensitive ECIS technology, corroborated with phalloidin immunocytochemistry data showing endothelial junction gap formations. Second, TNFa induces activation of two major survival pathways Akt and ERK, and stress-activated P38 MAPK in hMEC simultaneously. Third, we show for the first time that TNFa treatment results in a dose-dependent increase in the expression of another pro-inflammatory cytokine TSP-1 by the hMEC. Fourth, TNFa treatment results in decreased hMEC proliferation and viability, and increased apoptosis. Inhibitors of Akt and P38 MAPK, but not Mek/ERK blunted TNFa-induced TSP-1 expression in hMEC. Finally, genetic or pharmacological inhibition of NFjB did not exhibit any effect on TNFa-induced TSP-1 expression. Together, these results demonstrated that TNFa-mediated inflammatory stress in hMEC is mediated via activation of Akt and P38 MAPK, which is sustained through the expression of TSP-1 (Fig. 7) .
P38 MAPK, ERK, and Akt are 3 major signaling pathways activated in cells in response to many growth factors and cytokines [27] . However, there are conflicting reports on cross-talk between these 3 signaling pathways in various cell types and tissues [28] [29] [30] [31] [32] [33] . It is extremely rare to have P38 MAPK activated in conjunction with either Akt or ERK. In the current study, we report a highly rare scenario where TNFa is able to activate all the three serine-threonine kinases simultaneously in a dose-dependent manner. While TNFa is known to induce cell death via activation of death-receptor signaling-mediated extrinsic apoptosis pathway [34] , Akt pathway protects apoptosis via activation of Bcl2 expression and inhibition of intrinsic apoptosis pathway [35, 36] . Potential role of co-activation of Akt and ERK along with stress-induced P38 MAPK activation by TNFa is to reduce detrimental effects of P38 MAPK on hMEC apoptosis and proliferation during the inflammatory stress.
Increased expression of TSP-1 and its binding to CD47 has been reported to enhance monocyte binding to endothelial monolayer through enhanced expression of intracellular adhesion molecule-1 (ICAM1) and E-selectin [17] Furthermore, upon binding to CD36, TSP-1 induces receptor dimerization and CD36 activation [37] , thus eliciting an adhesive, anti-angiogenic and apoptotic response in endothelial cells [38] . Both these are important endothelial cell-specific steps essential for an inflammatory response. Although many clinical studies have suggested a correlation between TNFa activation and TSP-1 expression in inflammation, to our knowledge there are no existing reports demonstrating a causal relationship between TNFamediated activation and TSP-1 production in any cell types. A TNFa-308 G/A promoter polymorphism that activates TNFa gene expression is an underlying cause of many inflammatory diseases such as juvenile dermatomyositis [39, 40] and Crohn's disease [41] . Interestingly, the former studies have reported a correlation between TNFa activation and increased TSP-1 expression in juvenile dermatomyositis patients. However, these studies did Our previous studies have demonstrated that Akt is necessary for the expression of TSP-1 in endothelial cells [42] . In the current study, we show that both Akt and P38 MAPK cooperate in mediating TNFa-induced TSP-1 expression in hMEC. Since TNFa, Akt, and P38 MAPK have been implicated in the NFjB activation [34, [43] [44] [45] , a signaling mediator of inflammation, we presumed that NFjB activation downstream of Akt and P38 MAPK activation may be responsible for TNFa-induced TSP-1 expression in hMEC. However, our further analysis using piceatannol, a pharmacological NFjB inhibitor or NFjB SiRNA, exhibited no significant difference in the expression of TSP-1 in response to TNFa. Nevertheless, our results indicate the potential benefits of targeting TNFa and/ or TSP-1 for inflammatory diseases.
